Adlai Nortye Ltd.

Headquartered in North Brunswick, New Jersey, Adlai Nortye Ltd. (NASDAQ: ANL) drives the development of next-generation oncology treatments. Since its founding in 2004, the clinical-stage biopharmaceutical firm has focused on designing targeted therapies to overcome drug resistance in advanced tumors. By leveraging a dual research footprint spanning both the United States and China, the company aims to rewrite the treatment playbook for difficult-to-treat solid malignancies.

The company’s clinical pipeline features several precision therapies, including AN0025, a small molecule EP4 antagonist for rectal cancer, and AN4005, an oral small-molecule PD-L1 inhibitor. In early July 2026, the team achieved a significant milestone by dosing the first patient in the intermittent weekly dosing arm of its global Phase 1 trial for AN9025. This candidate operates as an oral pan-RAS(ON) inhibitor designed to target a broad spectrum of mutations in lung, colorectal, and pancreatic cancers.

In addition to small-molecule approaches, the organization leverages its proprietary platform to engineer AN4035, a specialized CEACAM5-targeting antibody-drug conjugate. Through its separate immuno-oncology division, the company also advances AN8025, a multi-functional tri-specific antibody fusion protein. As a result of a massive, oversubscribed private placement equity financing completed in April 2026, the company possesses the capital necessary to advance these global trials well into the future.